{"id":55097,"date":"2026-01-22T09:49:05","date_gmt":"2026-01-22T01:49:05","guid":{"rendered":"https:\/\/flcube.com\/?p=55097"},"modified":"2026-01-22T09:49:06","modified_gmt":"2026-01-22T01:49:06","slug":"bayer-partners-with-vanderbilt-in-5-year-deal-to-accelerate-cardio-renal-drug-discovery","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55097","title":{"rendered":"Bayer Partners with Vanderbilt in 5\u2011Year Deal to Accelerate Cardio\u2011Renal Drug Discovery"},"content":{"rendered":"\n<p><strong>Bayer AG<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/BAYN:ETR\">ETR:\u202fBAYN<\/a>) and <strong>Vanderbilt University Medical Center (VUMC)<\/strong> announced a <strong>strategic five\u2011year collaboration<\/strong> to advance innovative therapies from <strong>target identification through IND application<\/strong>, initially focusing on <strong>cardiovascular and kidney diseases<\/strong>\u2014two therapeutic areas with substantial unmet need.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure-amp-strategic-focus\">Deal Structure &amp; Strategic Focus<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Companies<\/strong><\/td><td>Bayer AG (global pharma) and Vanderbilt University Medical Center (academic medical center)<\/td><\/tr><tr><td><strong>Agreement Type<\/strong><\/td><td>5\u2011year strategic collaboration<\/td><\/tr><tr><td><strong>Focus Areas<\/strong><\/td><td>Cardiovascular diseases and kidney diseases<\/td><\/tr><tr><td>**VUMC Resources<\/td><td>BioVU collection of DNA and plasma, comprehensive clinical datasets<\/td><\/tr><tr><td>**Bayer Expertise<\/td><td>Drug discovery, translational sciences<\/td><\/tr><tr><td>**VUMC Expertise<\/td><td>Deep preclinical and clinical knowledge<\/td><\/tr><tr><td>**Goal<\/td><td>Advance therapies from target identification to IND filing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-amp-platform-synergy\">Technology &amp; Platform Synergy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>BioVU Advantage:<\/strong> VUMC\u2019s <strong>BioVU biobank<\/strong> contains <strong>>250,000 DNA samples<\/strong> linked to <strong>electronic health records<\/strong>, enabling <strong>data\u2011driven target identification<\/strong> and <strong>patient stratification<\/strong> for cardio\u2011renal diseases<\/li>\n\n\n\n<li><strong>Bayer\u2019s Translational Engine:<\/strong> Leverages <strong>in\u2011house screening, medicinal chemistry, and disease modeling<\/strong> to accelerate <strong>hit\u2011to\u2011lead optimization<\/strong><\/li>\n\n\n\n<li><strong>Collaborative Model:<\/strong> <strong>Joint steering committee<\/strong> with equal representation; VUMC principal investigators lead biology, Bayer manages chemistry and development<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> First academic\u2011pharma partnership to cover <strong>full spectrum from discovery to IND<\/strong> in cardio\u2011renal space<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competitive-landscape\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Cardiovascular Disease<\/th><th>Kidney Disease<\/th><\/tr><\/thead><tbody><tr><td><strong>Global Market (2030E)<\/strong><\/td><td>$120\u202fbillion<\/td><td>$95\u202fbillion<\/td><\/tr><tr><td>**Unmet Need<\/td><td>Residual risk post\u2011statin\/PCSK9; diabetic kidney disease progression<\/td><td><\/td><\/tr><tr><td>**Targeted Patient Population<\/td><td>180\u202fmillion (global)<\/td><td>85\u202fmillion (global)<\/td><\/tr><tr><td>**Bayer\u2011VUMC Pipeline Value<\/td><td>Estimated <strong>$2.5\u20113.5\u202fbillion<\/strong> in peak sales potential<\/td><td><\/td><\/tr><tr><td><strong>Deal Investment (Est.)<\/strong><\/td><td><strong>$150\u2011200\u202fmillion<\/strong> over 5 years (Bayer\u2011funded)<\/td><td><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Key Competitors:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pfizer-Broad Institute<\/strong> \u2013 Cardiovascular genomics partnership (target ID only)<\/li>\n\n\n\n<li><strong>Novartis-MIT<\/strong> \u2013 Kidney disease collaboration (pre\u2011clinical focus)<\/li>\n\n\n\n<li><strong>Bayer\u2011VUMC<\/strong> \u2013 <strong>First comprehensive deal<\/strong> covering <strong>target ID \u2192 IND<\/strong>, leveraging <strong>real\u2011world EHR\u2011linked biobank<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning\">Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pipeline Acceleration:<\/strong> Expected to <strong>shorten discovery\u2011to\u2011IND timeline<\/strong> from <strong>7\u20118\u202fyears to 4\u20115\u202fyears<\/strong> via AI\u2011driven target validation and VUMC\u2019s clinical insights<\/li>\n\n\n\n<li><strong>Financial Efficiency:<\/strong> <strong>Cost\u2011sharing model<\/strong> reduces Bayer\u2019s internal R&amp;D spend by <strong>20\u201130%<\/strong> while accessing <strong>de\u2011risked targets<\/strong><\/li>\n\n\n\n<li><strong>Risk Mitigation:<\/strong> VUMC\u2019s <strong>clinical expertise<\/strong> ensures early <strong>translational feasibility<\/strong> and <strong>patient population stratification<\/strong><\/li>\n\n\n\n<li><strong>Next Milestones:<\/strong><\/li>\n\n\n\n<li><strong>Target nomination:<\/strong> Q3\u202f2026<\/li>\n\n\n\n<li><strong>Lead optimization:<\/strong> H2\u202f2027<\/li>\n\n\n\n<li><strong>IND filing:<\/strong> Q4\u202f2028 (first candidate)<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding collaboration timelines, pipeline value, and cost savings. Actual results may differ due to scientific risks, competitive dynamics, and regulatory approval processes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bayer AG (ETR:\u202fBAYN) and Vanderbilt University Medical Center (VUMC) announced a strategic five\u2011year collaboration to&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[269,967],"class_list":["post-55097","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-bayer","tag-etr-bayn"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Bayer Partners with Vanderbilt in 5\u2011Year Deal to Accelerate Cardio\u2011Renal Drug Discovery - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Bayer AG (ETR:\u202fBAYN) and Vanderbilt University Medical Center (VUMC) announced a strategic five\u2011year collaboration to advance innovative therapies from target identification through IND application, initially focusing on cardiovascular and kidney diseases\u2014two therapeutic areas with substantial unmet need.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55097\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bayer Partners with Vanderbilt in 5\u2011Year Deal to Accelerate Cardio\u2011Renal Drug Discovery\" \/>\n<meta property=\"og:description\" content=\"Bayer AG (ETR:\u202fBAYN) and Vanderbilt University Medical Center (VUMC) announced a strategic five\u2011year collaboration to advance innovative therapies from target identification through IND application, initially focusing on cardiovascular and kidney diseases\u2014two therapeutic areas with substantial unmet need.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55097\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-22T01:49:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-22T01:49:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55097#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55097\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bayer Partners with Vanderbilt in 5\u2011Year Deal to Accelerate Cardio\u2011Renal Drug Discovery\",\"datePublished\":\"2026-01-22T01:49:05+00:00\",\"dateModified\":\"2026-01-22T01:49:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55097\"},\"wordCount\":391,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Bayer\",\"ETR: BAYN\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55097#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55097\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55097\",\"name\":\"Bayer Partners with Vanderbilt in 5\u2011Year Deal to Accelerate Cardio\u2011Renal Drug Discovery - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-22T01:49:05+00:00\",\"dateModified\":\"2026-01-22T01:49:06+00:00\",\"description\":\"Bayer AG (ETR:\u202fBAYN) and Vanderbilt University Medical Center (VUMC) announced a strategic five\u2011year collaboration to advance innovative therapies from target identification through IND application, initially focusing on cardiovascular and kidney diseases\u2014two therapeutic areas with substantial unmet need.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55097#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55097\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55097#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bayer Partners with Vanderbilt in 5\u2011Year Deal to Accelerate Cardio\u2011Renal Drug Discovery\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bayer Partners with Vanderbilt in 5\u2011Year Deal to Accelerate Cardio\u2011Renal Drug Discovery - Insight, China&#039;s Pharmaceutical Industry","description":"Bayer AG (ETR:\u202fBAYN) and Vanderbilt University Medical Center (VUMC) announced a strategic five\u2011year collaboration to advance innovative therapies from target identification through IND application, initially focusing on cardiovascular and kidney diseases\u2014two therapeutic areas with substantial unmet need.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55097","og_locale":"en_US","og_type":"article","og_title":"Bayer Partners with Vanderbilt in 5\u2011Year Deal to Accelerate Cardio\u2011Renal Drug Discovery","og_description":"Bayer AG (ETR:\u202fBAYN) and Vanderbilt University Medical Center (VUMC) announced a strategic five\u2011year collaboration to advance innovative therapies from target identification through IND application, initially focusing on cardiovascular and kidney diseases\u2014two therapeutic areas with substantial unmet need.","og_url":"https:\/\/flcube.com\/?p=55097","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-22T01:49:05+00:00","article_modified_time":"2026-01-22T01:49:06+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55097#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55097"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bayer Partners with Vanderbilt in 5\u2011Year Deal to Accelerate Cardio\u2011Renal Drug Discovery","datePublished":"2026-01-22T01:49:05+00:00","dateModified":"2026-01-22T01:49:06+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55097"},"wordCount":391,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Bayer","ETR: BAYN"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55097#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55097","url":"https:\/\/flcube.com\/?p=55097","name":"Bayer Partners with Vanderbilt in 5\u2011Year Deal to Accelerate Cardio\u2011Renal Drug Discovery - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-22T01:49:05+00:00","dateModified":"2026-01-22T01:49:06+00:00","description":"Bayer AG (ETR:\u202fBAYN) and Vanderbilt University Medical Center (VUMC) announced a strategic five\u2011year collaboration to advance innovative therapies from target identification through IND application, initially focusing on cardiovascular and kidney diseases\u2014two therapeutic areas with substantial unmet need.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55097#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55097"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55097#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bayer Partners with Vanderbilt in 5\u2011Year Deal to Accelerate Cardio\u2011Renal Drug Discovery"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55097","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55097"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55097\/revisions"}],"predecessor-version":[{"id":55098,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55097\/revisions\/55098"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55097"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55097"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55097"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}